Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (November 2025)
16 slides from Imugene's shareholder meeting presentation, Nov 13, 2025
Slide 1: Annual General Meeting November 2025
ASX:IMU For personal use only Annual General Meeting November 2025 1
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal Neither the Company nor any of its directors, officers, employees, investment advice. The presentation is not intended to be advisers, associated persons or subsidiaries are liable for any direct, comprehensive or provide a
Slide 3: Azer-cel Allogeneic CD19 CAR T for Blood Cancer
For personal use only Azer-cel Allogeneic CD19 CAR T for Blood Cancer 3
Slide 4: Two Types of CAR-T Cell Therapy: Auto and Allo
Two Types of CAR-T Cell Therapy: Auto and Allo Potential First-in-class Off-the-shelf Allogeneic CAR-T Cell Therapy significantly differentiated from approved Auto CAR-T Therapies For personal use only Autologous – 4+ FDA approved products in CD19 • Auto CAR-T cells are made from the patient’s own T
Slide 5: Compelling Phase 1b Data
Compelling Phase 1b Data 81% Overall Response Rate in Relapsed/Refractory (R/R) DLBCL Date of Release Evaluable Treatment N Overall Response Best Durability KEY DATA patients Rate (ORR) (Time of response) • Phase 1b trial continues to enrol For personal use only Lymphodepletion patients across leadi
Slide 6: Azer-cel 81% Overall Response Rate N=16
Azer-cel 81% Overall Response Rate N=16 DLBCL CAR T relapsed patients Best Response For personal use only CR CR CR CR CR CR CR PR PR PR PR PR PR SD SD PD Durability 560+ 440+ 185+ *148+ 155 90 90 *67+ 90 60 60 60 60 Days Days Days Days Days Days Days Days Days Days Days Days Days *Allo transplant at
Slide 7: Comparison to Existing Approved Auto CAR-T Therapies
Comparison to Existing Approved Auto CAR-T Therapies Initial azer-cel Ph 1b R/R DLBCL data compelling when compared to approved Auto CAR-T treatments For personal use only Product Indication Complete Best Durability of FDA benchmark1 for approval in heavily pre-treated Response (CR) Response3 (DoR)
Slide 8: Encouraging Clinical Activity
Encouraging Clinical Activity Azer-cel demonstrates responses similar to approved Autologous CD19 CAR T products For personal use only 90 80 70 81% 74% 73% 60 Overall 50 Response 52% Rate % 40 R/R DLBCL 30 20 10 0 Azer-cel Yescarta Breyanzi Kymriah (Axi-cel) (Liso-cel) (Tisa-cel) Despite all patient
Slide 9: Safety Summary: CAR-T Associated Adverse Events
Safety Summary: CAR-T Associated Adverse Events No Evidence of GvHD or Gr. ≥3 CRS – Safety Profile is very manageable For personal use only 9
Slide 10: Patient Case Study: Cancer Free for 560+ Days
Patient Case Study: Cancer Free for 560+ Days Complete Response for an azer-cel patient that failed 4 prior lines of therapy including auto CAR-T. Durability of Response now out to 560+ days and patient currently remains cancer free For personal use only Tumour Tumor-free Baseline Day 515+ PATIENT T
Slide 11: Azer-cel 83% Overall Response Rate N=6
Azer-cel 83% Overall Response Rate N=6 CAR T Naïve Lymphomas Overall Best Durability Date of Evaluable Treatment N Response (Time of Best Response Release patients Rate (ORR) response) For personal use only Lymphodepletion CR CR CR October Update CAR T Naïve Lymphomas (LD)1 +azer-cel +Interleukin-2
Slide 12: Azer-cel Commercialization Opportunity
Azer-cel Commercialization Opportunity $2bn+ p.a US market opportunity with no approved CAR-T therapies in rare lymphomas and relapsed CAR-T therapy patients AZER CEL US INCIDENCE 1 ELIGIBLE FOR CAR T 2 MARKET OPPORTUNITY For personal use only MZL, 4,500 ($Millions) 3 WM, 1,000 DLBCL/HGBCL, MZL, 1,2
Slide 13: Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR T
Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR T Opportunity to initiate a pivotal clinical trial in 2026 A Phase 1a clinical trial in Lymphoma & Leukaemia with 84 patients was completed by Precision Biosciences in 2023 and delivered promising results For personal use only • • Imugene is cu
Slide 14: Key Achievements and Expected Upcoming Milestones
Key Achievements and Expected Upcoming Milestones Key Achievements Expected Upcoming Milestones azer-cel azer-cel For personal use only January 2025: First Aus site opened for R/R Q4 Calendar Year 2025 DLBCL clinical trial and first DLBCL patient • Planned FDA Meeting for R/R DLBCL dosed in AUS regi
Slide 15: Experienced Leadership Team has Brought 18+ FDA-Approved Drugs to Market
Experienced Leadership Team has Brought 18+ FDA-Approved Drugs to Market For personal use only Darren Keamy Chief Financial Officer and Company Secretary BOARD OF DIRECTORS Leslie Chong John Byon, MD, PhD Bradley Glover, Ursula McCurry Paul Hopper Chief Executive Officer Chief Medical Officer PhD, M
Slide 16: For personal use only
ASX : IMU imugene.com For personal use only Connect with us on LinkedIn @Imugene Limited Follow us on X (Twitter) @TeamImugene Watch us on YouTube @ImugeneLimited 16